Previous 10 | Next 10 |
DocuSign Inc. (DOCU) is expected to report $0.11 for Q2 2024 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Concrete Pumping Holdings Inc. (BBCP) is expected to report $0.16 for Q3 2023 ...
Protagenic Therapeutics Inc. (PTIX) is expected to report for quarter end 2023-06-30
2023-03-23 10:06:23 ET Gainers: ZyVersa Therapeutics ( ZVSA ) +33% . Aziyo Biologics ( AZYO ) +29% . Generation Bio ( GBIO ) +20% . HTG Molecular Diagnostics ( HTGM ) +16% . scPharmaceuticals ( SCPH ) +15% . Losers:...
2023-03-22 16:09:07 ET Protagenic Therapeutics ( NASDAQ: PTIX ) on Wednesday announced it has approved a 1-for-4 reverse stock split of the company's issued and outstanding common stock. The reverse stock split will not reduce the number of authorized shares of common stock or...
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESSWIRE / March 22, 2023 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX, the "Company") a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, to...
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B. Riley Securities Neuro and Ophthal...
Protagenic Therapeutics (NASDAQ:PTIX): Q3 GAAP EPS of -$0.05 beats by $0.03. Cash and cash equivalents of ~$10.8M Press Release For further details see: Protagenic Therapeutics EPS beats by $0.03
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the third quarter ended September 30, 2021. Recent Highlights ...
BEST BEST +22% offloads its express business in China to J&T Express in a deal value of RMB6.8B WiMi Hologram Cloud (NASDAQ:WIMI) +20% submitted the trademark application of "WIMI METAVERSE" to lay out the rapidly developing Metaverse industry IonQ (NYSE:IONQ) +15%. Exela T...
Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and A ddiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biophar...
News, Short Squeeze, Breakout and More Instantly...
Protagenic Therapeutics Inc. Company Name:
PTIX Stock Symbol:
OTCMKTS Market:
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating n...
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a tal...
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion Plans to enroll final tw...